Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-36279 CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 75-3175693 (State or other jurisdiction of incorpo ...

Welcome to Cara Therapeutics 2022 R&D Day MARCH 11, 2022 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forwardlooking statements include statements concerning the expected timing of the initiation, enrollment and data readouts from the Company's planned and ongoing clinical trials, the potential results of ongoin ...

Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Iris Francesconi - Interim Head, Investor Relations Christopher Posner - President, CEO & Director Thomas Reilly - CFO Joana Goncalves - Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Company Nicholas Rubino - Stifel, Nicolaus & Company Sumant Kulkarni - Canaccord Genuity Chi Zhang - Bank of America Merrill Lynch Daniel Wolle - JPMorgan Chase & Co. David Amsell ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-36279 CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 75-3175693 (State or other jurisdiction of incorporation or organ ...

Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2021 Earnings Conference Call November 8, 2021 4:30 PM ET Company Participants William Gramig - Stern Investor Relations Derek Chalmers - President and Chief Executive Officer Christopher Posner - Incoming CEO Thomas Reilly - Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Chris Howerton - Jefferies David Amsellem - Piper Sandler Annabel Samimy - Stifel Operator Good afternoon and welcome to Cara Therapeutics’ Third Quarter 2021 Financial ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-36279 CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 75-3175693 (State or other jurisdiction of inc ...

Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Cole Herlitz-Ferguson - Stern Investor Relations Derek Chalmers - President and Chief Executive Officer Thomas Reilly - Chief Financial Officer Conference Call Participants Jessica Fye - J.P. Morgan Chris Howerton - Jefferies David Amsellem - Piper Sandler Jason Gerberry - Bank of America Jack Padovano - Stifel Oren Livnat - H.C. Wainwright Operator Good afternoon and welcome to the Cara The ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-36279 CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 75-3175693 (State or other jurisdiction of incorpor ...

Targeting Pruritus with First-In-Class Therapeutics MAY 10, 2021 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forwardlooking statements include statements concerning the expected timing of the enrollment and data readouts from the Company's ongoing clinical trials, the potential results of ongoing clinical trial ...

Financial Data and Key Metrics Changes - Cash, cash equivalents, and marketable securities totaled $228.3 million as of March 31, 2021, down from $251.5 million at December 31, 2020, primarily due to cash used in operating activities of $23.7 million [26] - Net loss for Q1 2021 was $23.3 million or $0.47 per share, compared to a net loss of $28.9 million or $0.62 per share for the same period in 2020 [27] - Total revenue for Q1 2021 was $1.9 million, a decrease from $8.1 million in Q1 2020, with revenue related to a milestone payment from Maruishi Pharmaceutical [27] Business Line Data and Key Metrics Changes - Research and development expenses were $19.1 million for Q1 2021, down from $33.5 million in the same period of 2020, mainly due to decreased clinical trial costs [28] - General and administrative expenses increased to $6.4 million in Q1 2021 from $4.6 million in Q1 2020, attributed to higher stock compensation and payroll costs [28] Market Data and Key Metrics Changes - The European Medicines Agency accepted the Marketing Authorization Application for difelikefalin Injection for chronic kidney disease-related pruritus, with a decision expected in Q2 2022 [11] Company Strategy and Development Direction - The company is focused on the U.S. launch of KORSUVA Injection in the second half of 2021, supported by a commercial license agreement with Vifor Pharma [8][9] - Plans to initiate Phase 3 programs for Oral KORSUVA in mild to moderate atopic dermatitis and pre-dialysis CKD patients by year-end [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming PDUFA date of August 23, 2021, for KORSUVA Injection, with no current issues regarding site inspections [32] - The company aims to leverage existing data from hemodialysis patients to support the approval of Oral KORSUVA in pre-dialysis CKD patients [49] Other Important Information - The company expects its existing cash and equivalents to fund operations into 2023 without considering potential milestone payments or product revenue [29] - The company is implementing measures to minimize disruptions to clinical studies due to the COVID-19 pandemic [19] Q&A Session Summary Question: Any CMC site inspection issues regarding KORSUVA Injection? - Management indicated no current issues with site inspections and remains on track for the PDUFA date [32] Question: Insights on the oral CKD trial and Stage 5 patient population? - Management noted that Stage 5 patients have similar prevalence rates of pruritus as hemodialysis patients, indicating a strong potential for Oral KORSUVA [32] Question: How does the company view the potential for KORSUVA Injection compared to Parsabiv? - Management believes KORSUVA Injection has a better positioning as a first-in-class medication for hemodialysis patients, with significant unmet needs [40] Question: What is the expected placebo response rate in the PBC trial? - Management expects a more controlled placebo response in PBC patients due to the consistency of pruritus in this population [54] Question: Will Stage 4 patients be included in the Phase 3 program? - Management is in discussions with the FDA to include Stage 4 patients alongside Stage 5 in the Phase 3 program [58] Question: How will the commercialization strategy differ between Oral KORSUVA and KORSUVA Injection? - Management indicated that capturing pre-dialysis patients earlier in the treatment cycle would enhance the commercialization strategy [50]